New drug in leukaemia fight

A new anti-cancer medication has been approved by the TGA for treatment of the most common type of leukaemia in Australia Venclexta (venetoclax) is a once-daily oral B-cell lymphoma-2 inhibitor that has been approved by the TGA this month, for use by patients with harder-to-treat forms of chronic lymphocytic leukaemia. The decision is a “major milestone”

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Guild calls on Pharmacy Review to "come clean"
Next Keep up to date with technology